Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Non-Current Assets for 9 consecutive years, with $173.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Assets fell 70.43% to $173.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 billion, a 29.6% decrease, with the full-year FY2024 number at $509.7 million, up 467.77% from a year prior.
  • Non-Current Assets was $173.0 million for Q3 2025 at Denali Therapeutics, down from $231.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $607.5 million in Q1 2024 to a low of $81.7 million in Q2 2023.
  • A 5-year average of $278.8 million and a median of $177.9 million in 2022 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: plummeted 82.66% in 2022, then skyrocketed 621.67% in 2024.
  • Denali Therapeutics' Non-Current Assets stood at $506.9 million in 2021, then tumbled by 82.66% to $87.9 million in 2022, then increased by 2.11% to $89.8 million in 2023, then surged by 467.77% to $509.7 million in 2024, then tumbled by 66.06% to $173.0 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Non-Current Assets are $173.0 million (Q3 2025), $231.5 million (Q2 2025), and $392.7 million (Q1 2025).